Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Enterococcus Faecium Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Enterococcus Faecium Infections - Pipeline Review, H2 2014', provides an overview of the Enterococcus Faecium Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Enterococcus Faecium Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Enterococcus Faecium Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Enterococcus Faecium Infections Overview 6 Therapeutics Development 7 Pipeline Products for Enterococcus Faecium Infections - Overview 7 Pipeline Products for Enterococcus Faecium Infections - Comparative Analysis 8 Enterococcus Faecium Infections - Therapeutics under Development by Companies 9 Enterococcus Faecium Infections - Therapeutics under Investigation by Universities/Institutes 10 Enterococcus Faecium Infections - Pipeline Products Glance 11 Early Stage Products 11 Enterococcus Faecium Infections - Products under Development by Companies 12 Enterococcus Faecium Infections - Products under Investigation by Universities/Institutes 13 Enterococcus Faecium Infections - Companies Involved in Therapeutics Development 14 ConjuGon, Inc. 14 ContraFect Corporation 15 Melinta Therapeutics, Inc 16 Novan, Inc. 17 Omnia Molecular Ltd. 18 Sumitomo Dainippon Pharma Co., Ltd. 19 Enterococcus Faecium Infections - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 26 Drug Profiles 28 CF-304 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 chrysophaentin - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 GP-505 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 NVN-4428 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 RX-04 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 RX-05 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 RXP-873 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 SB-204 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 SM-295291 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 SM-369926 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Enterococcus Faecium Infections - Recent Pipeline Updates 39 Enterococcus Faecium Infections - Dormant Projects 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables Number of Products under Development for Enterococcus Faecium Infections, H2 2014 7 Number of Products under Development for Enterococcus Faecium Infections - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Products under Investigation by Universities/Institutes, H2 2014 13 Enterococcus Faecium Infections - Pipeline by ConjuGon, Inc., H2 2014 14 Enterococcus Faecium Infections - Pipeline by ContraFect Corporation, H2 2014 15 Enterococcus Faecium Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 16 Enterococcus Faecium Infections - Pipeline by Novan, Inc., H2 2014 17 Enterococcus Faecium Infections - Pipeline by Omnia Molecular Ltd., H2 2014 18 Enterococcus Faecium Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Mechanism of Action, H2 2014 24 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 27 Enterococcus Faecium Infections Therapeutics - Recent Pipeline Updates, H2 2014 39 Enterococcus Faecium Infections - Dormant Projects, H2 2014 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.